MCID: NRV006
MIFTS: 60

Nervous System Cancer

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Nervous System Cancer

MalaCards integrated aliases for Nervous System Cancer:

Name: Nervous System Cancer 12 15 17
Neuroepithelial, Perineurial, and Schwann Cell Neoplasm 74
Malignant Neoplasm of Nervous System 12
Neoplasm of the Nervous System 30
Tumor of the Nervous System 12
Neoplasm of Nervous System 12
Nervous System Neoplasms 74
Nervous System Neoplasm 12
Neoplasms, Nerve Tissue 45
Nervous System--Cancer 74
Nervous System Tumor 56
Neural Neoplasm 12
Neural Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3093
ICD9CM 36 192 192.9
MeSH 45 D009380
NCIt 51 C35562

Summaries for Nervous System Cancer

Disease Ontology : 12 An organ system cancer located in the nervous system that affects the central or peripheral nervous system.

MalaCards based summary : Nervous System Cancer, also known as neuroepithelial, perineurial, and schwann cell neoplasm, is related to autonomic nervous system neoplasm and central nervous system cancer. An important gene associated with Nervous System Cancer is CDKN2B-AS1 (CDKN2B Antisense RNA 1), and among its related pathways/superpathways are ERK Signaling and Cell Cycle, Mitotic. The drugs Tramadol and Morphine have been mentioned in the context of this disorder. Affiliated tissues include brain, pituitary and bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Nervous System Cancer

Diseases in the Nervous System Cancer family:

Central Nervous System Cancer

Diseases related to Nervous System Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 260)
# Related Disease Score Top Affiliating Genes
1 autonomic nervous system neoplasm 34.5 CASP3 ENO2 MYCN NUMBL TP53
2 central nervous system cancer 34.3 CDKN2A ENO2 IDH1 MGMT MYCN NF1
3 oligodendroglioma 32.0 CDKN2A CDKN2B ENO2 IDH1 MGMT TP53
4 peripheral nervous system neoplasm 32.0 CASP3 ENO2 MYCN NF1 NF2 NUMBL
5 ewing sarcoma 31.8 CASP3 CCND1 CDK2 CDK4 CDKN2A ENO2
6 brain cancer 31.6 CASP3 CDK4 ENO2 IDH1 MGMT MYCN
7 pleomorphic xanthoastrocytoma 30.6 IDH1 MGMT TP53
8 ependymoma 30.6 ENO2 MGMT NF2 RB1
9 neurofibromatosis, type iv, of riccardi 30.5 CDKN2B-AS1 NF1 NF2
10 ewing's family of tumors 30.5 CDK4 CDKN2A CDKN2B RB1
11 neurofibroma 30.5 CDKN2A NF1 NF2
12 spinal meningioma 30.4 ENO2 NF1 NF2
13 meningioma, familial 30.3 CDKN2A ENO2 NF1 NF2 TP53
14 leiomyosarcoma 30.1 CDK4 ENO2 TP53
15 breast cancer 30.1 CASP3 CCND1 CDK2 CDK4 CDKN2B-AS1 IDH1
16 esophageal cancer 30.1 CASP3 CCND1 CDK4 CDKN2A CDKN2B CDKN2B-AS1
17 rhabdomyosarcoma 30.1 CDK4 ENO2 MYCN TP53
18 spindle cell lipoma 30.0 CDK4 RB1
19 glioma 29.9 CCND1 CDK4 CDKN2A CDKN2B-AS1 IDH1 NF1
20 medulloblastoma 29.8 CASP3 CCND1 CDK4 CDKN2B CDKN2B-AS1 ENO2
21 olfactory neural tumor 12.2
22 glioma susceptibility 1 11.2
23 rapid-onset childhood obesity-hypothalamic dysfunction-hypoventilation-autonomic dysregulation syndrome 11.1
24 mismatch repair cancer syndrome 11.1
25 neuroblastoma 1 11.0
26 glioma susceptibility 2 11.0
27 glioma susceptibility 3 11.0
28 glioma susceptibility 9 11.0
29 central nervous system hematologic cancer 11.0
30 schwannomatosis 1 11.0
31 central neurocytoma 11.0
32 neurilemmomatosis 11.0
33 ectomesenchymoma 11.0
34 malignant ectomesenchymoma 11.0
35 central nervous system primitive neuroectodermal neoplasm 11.0
36 sensory system cancer 11.0
37 central nervous system sarcoma 11.0
38 cranial nerve neoplasm 11.0
39 central nervous system germ cell tumor 11.0
40 central nervous system melanocytic neoplasm 11.0
41 central nervous system mesenchymal non-meningothelial tumor 11.0
42 spinal cancer 11.0
43 spitz nevus 10.7 CDKN2A TP53
44 askin's tumor 10.6 ENO2 MYCN
45 atypical follicular adenoma 10.6 ENO2 TP53
46 skin carcinoma in situ 10.6 CCND1 CDKN2A
47 vulvar adenocarcinoma 10.6 RB1 TP53
48 plexiform neurofibroma 10.6 CDKN2B-AS1 NF1 NF2
49 gliofibroma 10.6 NF1 TP53
50 ring chromosome 7 10.6 CDK4 TP53

Graphical network of the top 20 diseases related to Nervous System Cancer:



Diseases related to Nervous System Cancer

Symptoms & Phenotypes for Nervous System Cancer

GenomeRNAi Phenotypes related to Nervous System Cancer according to GeneCards Suite gene sharing:

27 (show all 23)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.03 RB1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.03 MGMT
3 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.03 RB1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.03 CCND1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.03 RB1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.03 CCND1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.03 CCND1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.03 CCND1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.03 RB1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.03 CCND1 RB1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.03 CCND1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.03 CCND1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.03 CCND1 MGMT RB1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.03 CCND1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.03 CCND1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-37 10.03 MGMT
17 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.03 RB1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-5 10.03 MGMT
19 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.03 RB1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.03 RB1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-92 10.03 MGMT
22 Decreased viability in esophageal squamous lineage GR00235-A 9.85 BCHE CCND1 CDK2 CDKN2A IDH1 MYCN
23 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.02 CDK2 CDK4 ENO2 MYCN RBL1

MGI Mouse Phenotypes related to Nervous System Cancer:

47 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.49 CASP3 CCND1 CDK2 CDK4 CDKN2A CDKN2B
2 homeostasis/metabolism MP:0005376 10.49 BCHE CASP3 CCND1 CDK2 CDK4 CDKN2A
3 growth/size/body region MP:0005378 10.46 CASP3 CCND1 CDK2 CDK4 CDKN2A ENO2
4 mortality/aging MP:0010768 10.46 BCHE CASP3 CCND1 CDK2 CDK4 CDKN2A
5 behavior/neurological MP:0005386 10.44 CASP3 CCND1 CDK4 CDKN2A ENO2 MYCN
6 endocrine/exocrine gland MP:0005379 10.4 CASP3 CCND1 CDK2 CDK4 CDKN2A CDKN2B
7 hematopoietic system MP:0005397 10.38 CASP3 CCND1 CDK2 CDK4 CDKN2A CDKN2B
8 cardiovascular system MP:0005385 10.36 CASP3 CCND1 CDK2 CDK4 CDKN2A MYCN
9 immune system MP:0005387 10.36 CASP3 CCND1 CDK2 CDK4 CDKN2A CDKN2B
10 embryo MP:0005380 10.34 CDK2 CDK4 CDKN2A MYCN NF1 NF2
11 craniofacial MP:0005382 10.31 CASP3 CCND1 ENO2 MYCN NF1 NF2
12 integument MP:0010771 10.31 CASP3 CCND1 CDK2 CDK4 CDKN2A CDKN2B
13 digestive/alimentary MP:0005381 10.3 CASP3 CCND1 CDK4 CDKN2A MYCN NF1
14 nervous system MP:0003631 10.27 CASP3 CCND1 CDK4 CDKN2A ENO2 MYCN
15 neoplasm MP:0002006 10.26 CCND1 CDK2 CDK4 CDKN2A CDKN2B MGMT
16 liver/biliary system MP:0005370 10.22 CDK2 CDK4 CDKN2A MYCN NF1 NF2
17 muscle MP:0005369 10.19 CASP3 CDK2 CDK4 CDKN2A MYCN NF1
18 hearing/vestibular/ear MP:0005377 10.18 CASP3 NF1 NF2 NUMBL RB1 RBL1
19 reproductive system MP:0005389 10.1 BCHE CASP3 CCND1 CDK2 CDK4 CDKN2A
20 no phenotypic analysis MP:0003012 10.09 CASP3 CDKN2A CDKN2B MGMT MYCN RB1
21 normal MP:0002873 10.06 CCND1 CDK4 MYCN NF1 NUMBL RB1
22 renal/urinary system MP:0005367 10.02 CASP3 CDK4 CDKN2B MYCN NF1 NF2
23 respiratory system MP:0005388 9.97 CASP3 CCND1 CDKN2A ENO2 IDH1 MGMT
24 pigmentation MP:0001186 9.85 CASP3 CDK4 CDKN2A NF1 RB1 TP53
25 skeleton MP:0005390 9.7 CASP3 CCND1 CDKN2A IDH1 MYCN NF1
26 vision/eye MP:0005391 9.4 CASP3 CCND1 CDK2 CDK4 CDKN2A MYCN

Drugs & Therapeutics for Nervous System Cancer

Drugs for Nervous System Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 747)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
2
Morphine Approved, Investigational Phase 4,Phase 2,Not Applicable 57-27-2 5288826
3
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 113775-47-6 5311068 68602
4
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
5
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
6
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-03-3
7
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-23-7 5754
8
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
9
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 85622-93-1 5394
10
Cytarabine Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4, 65-46-3 6253
11
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 28523-86-6 5206
12
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 2078-54-8 4943
13
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
14
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 83150-76-9 6400441 383414
15
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
16
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 38396-39-3, 2180-92-9 2474
17
Thrombin Approved, Investigational Phase 4
18
Remifentanil Approved Phase 4,Phase 3,Not Applicable 132875-61-7 60815
19
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
20
Oxycodone Approved, Illicit, Investigational Phase 4,Not Applicable 76-42-6 5284603
21
Acetaminophen Approved Phase 4,Phase 2,Phase 1 103-90-2 1983
22
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
23
Ibuprofen Approved Phase 4 15687-27-1 3672
24
Levetiracetam Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 102767-28-2 441341
25
Hydralazine Approved Phase 4 86-54-4 3637
26
Clevidipine Approved, Investigational Phase 4 167221-71-8
27
Labetalol Approved Phase 4 36894-69-6 3869
28
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 113-45-1 4158
29
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
30
Mitoxantrone Approved, Investigational Phase 4,Phase 1 65271-80-9 4212
31
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
32
Lidocaine Approved, Vet_approved Phase 4,Phase 1 137-58-6 3676
33
Sulfamethoxazole Approved Phase 4,Phase 1 723-46-6 5329
34
Trimethoprim Approved, Vet_approved Phase 4,Phase 1 738-70-5 5578
35
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 38916-34-6, 51110-01-1 53481605
36
Pasireotide Approved Phase 4,Phase 2,Phase 3 396091-73-9 9941444
37
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
38
Cefdinir Approved Phase 4 91832-40-5 6915944
39
Cefazolin Approved Phase 4 25953-19-9 33255 656510
40
Cefuroxime Approved Phase 4 55268-75-2 5479529 5361202
41
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
42
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-70-2 271
43
Glutamic Acid Approved, Nutraceutical Phase 4,Not Applicable 56-86-0 33032
44
Lactitol Investigational Phase 4,Phase 2 585-88-6, 585-86-4 493591
45 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Not Applicable
48 Narcotics Phase 4,Phase 3,Phase 2,Not Applicable
49 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Dexketoprofen trometamol Phase 4

Interventional clinical trials:

(show top 50) (show all 1969)
# Name Status NCT ID Phase Drugs
1 Single Dose Tramadol Effect on Extubation Response and Quality of Emergence Post-supratentorial Intracranial Surgery Unknown status NCT02964416 Phase 4 Injection Tramadol
2 Comparison of Efficacy and Safety of the Postoperative Analgesia Methods Unknown status NCT02929147 Phase 4 Morphine;Dexketoprofen;Placebo
3 Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach Unknown status NCT03132259 Phase 4 high dose dexmedethomidine;low dose dexmedethomidine
4 Different Dose of Methotrexate for the Treatment of Meningeal Carcinomatosis Unknown status NCT02590510 Phase 4 methotrexate
5 Cavernous Sinus Dissection and Bleeding in Meningiomas Unknown status NCT02863484 Phase 4
6 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Unknown status NCT02478346 Phase 4 Fluorescein Sodium
7 Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery Unknown status NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
8 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Unknown status NCT02379754 Phase 4 Gentamicins
9 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
10 Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System Completed NCT02343081 Phase 4 Temozolomide;Temozolomide
11 Validation of 3 Dimensional Laparoscopic System in Disral Pancreatectomy and Splenectomy Completed NCT02757690 Phase 4
12 DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor Completed NCT00029523 Phase 4 Intrathecal (injected into the spinal fluid) DepoCyt;Intrathecal methotrexate;Intrathecal cytarabine (also known as ara-C)
13 Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy Completed NCT02810899 Phase 4 dexmedetomidine;normal saline
14 Sugammadex Given for the Reversal of Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants Completed NCT02708056 Phase 4 Sugammadex
15 Scalp Nerve Block and Opioid Consumption in Brain Surgery Completed NCT02057367 Phase 4 Scalp block with 0.5% plain Marcaine;Scalp block with 0.9% normal saline
16 Phase IV Bioseal Study in Brain Tumor Surgery Completed NCT02034799 Phase 4
17 Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors Completed NCT02034708 Phase 4 Dotarem®;Gadovist®/Gadavist®
18 Remifentanil Infusion Alone During the Closure Period for Early Emergence Following Craniotomy Completed NCT02593942 Phase 4 Remifentanil;Propofol
19 Multihance at 3 Tesla in Brain Tumors Completed NCT00395863 Phase 4 Multihance;Arm 2 - Magnevist
20 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
21 Perampanel in Seizure Patients With Primary Glial Brain Tumors Completed NCT02363933 Phase 4 Perampanel
22 Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor (IV Ibuprofen);IV Ibuprofen placebo
23 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
24 Trial of Levetiracetam in Patients With Primary Brain Tumors and Symptomatic Seizures Who Undergo Surgery Completed NCT00571155 Phase 4 levetiracetam
25 Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors Completed NCT00075166 Phase 4
26 A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients Completed NCT00952081 Phase 4 Clevidipine
27 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4 Methylphenidate
28 NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate Completed NCT00169611 Phase 4 methylphenidate
29 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
30 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4 interferon beta 1a 30 ug IM once weekly
31 1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients Recruiting NCT02334722 Phase 4 Levetiracetam extended release
32 Dexmedetomidine and Propofol for Pediatric MRI Sedation Recruiting NCT03513757 Phase 4 propofol;Dexmedetomidine
33 Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
34 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4 Gentamicin
35 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
36 Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. Not yet recruiting NCT03190122 Phase 4
37 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Terminated NCT02028325 Phase 4 Fluorescein Sodium
38 Treatment of Resectable Malignant Brain Tumors Terminated NCT00415467 Phase 4
39 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
40 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
41 Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
42 Carboplatin Plus Vincristine in Treating Children and Adolescents With Low Grade Glioma Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
43 Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma Unknown status NCT00053872 Phase 3 cisplatin;lomustine;vincristine sulfate
44 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
45 3D Ultra Sound for Resection of Brain Tumors Unknown status NCT02150564 Phase 3
46 Prevention of Imminent Paralysis Following Spinal Cord Trauma or Ischemia by Minocycline: A Multi-center Study in Israel With IDF Primary Care Involvement Unknown status NCT01813240 Phase 2, Phase 3 Minocycline;placebo
47 Efficacy of Tranexamic Acid in Brain Tumor Resections Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
48 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
49 Stereotactic Radiotherapy of Resection Cavity For Single Brain Metastasis Versus Whole-Brain Radiotherapy After Resection Unknown status NCT01535209 Phase 3
50 Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases) Unknown status NCT02338011 Phase 2, Phase 3 Gefitinib

Search NIH Clinical Center for Nervous System Cancer

Cochrane evidence based reviews: neoplasms, nerve tissue

Genetic Tests for Nervous System Cancer

Genetic tests related to Nervous System Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of the Nervous System 30

Anatomical Context for Nervous System Cancer

MalaCards organs/tissues related to Nervous System Cancer:

42
Brain, Pituitary, Bone, T Cells, Testes, Spinal Cord, Bone Marrow

The Foundational Model of Anatomy Ontology organs/tissues related to Nervous System Cancer:

20
The Nervous System

Publications for Nervous System Cancer

Articles related to Nervous System Cancer:

(show all 28)
# Title Authors Year
1
Neuropsychological disorders in non-central nervous system cancer: a review of objective cognitive impairment, depression, and related rehabilitation options. ( 31049790 )
2019
2
Racial and ethnic differences in survival of pediatric patients with brain and central nervous system cancer in the United States. ( 30350913 )
2019
3
Exosomes impact survival to radiation exposure in cell line models of nervous system cancer. ( 30546829 )
2018
4
Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: protocol for a scoping review. ( 29374660 )
2018
5
Brain cortical structural differences between non-central nervous system cancer patients treated with and without chemotherapy compared to non-cancer controls: a cross-sectional pilot MRI study using clinically-indicated scans. ( 30034079 )
2017
6
The Complex Diagnostic Challenge in Children With Non-Central Nervous System Cancer and Cerebellar Mutism. ( 28497710 )
2017
7
Meta-Analysis of the Effects of Neuropsychological Interventions on Cognitive Function in Non-Central Nervous System Cancer Survivors. ( 27151596 )
2016
8
Five-year relative survival rate of brain and other nervous system cancer in the USA, Europe and Japan. ( 25717112 )
2015
9
Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. ( 25483452 )
2015
10
Brain and central nervous system cancer incidence in navarre (Spain), 1973-2008 and projections for 2014. ( 25561983 )
2015
11
Identification of miRNAs as potential new biomarkers for nervous system cancer. ( 25139093 )
2014
12
Vocational identity, positive affect, and career thoughts in a group of young adult central nervous system cancer survivors. ( 25035908 )
2014
13
Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patients. ( 23661397 )
2013
14
Comparison of time trends in brain and central nervous system cancer mortality (1990-2006) between countries based on the WHO mortality database. ( 21273379 )
2011
15
Medulloblastoma and Brucellosis - Molecular Evidence of Brucella sp in Association with Central Nervous System Cancer. ( 21475718 )
2011
16
Long-term health experience of jet engine manufacturing workers: IV. A comparison of central nervous system cancer ascertainment using mortality and incidence data. ( 20816315 )
2010
17
Pain in children with central nervous system cancer: a review of the literature. ( 20591796 )
2010
18
Induction of cytotoxicity, apoptosis and cell cycle arrest by 1-t-butyl carbamoyl, 7-methyl-indole-3-ethyl isothiocyanate (NB7M) in nervous system cancer cells. ( 19920894 )
2009
19
School-aged children after the end of successful treatment of non-central nervous system cancer: longitudinal assessment of health-related quality of life, anxiety and coping. ( 19594611 )
2009
20
Molecular predictors of human nervous system cancer responsiveness to enediyne chemotherapy. ( 18338171 )
2008
21
Comparison of time trends in brain central nervous system cancer incidence (1973-97) in East Asia, Europe and USA, from Cancer Incidence in Five Continents Vols IV-VIII. ( 18772173 )
2008
22
Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. ( 18415683 )
2008
23
Cytotoxicity and oncostatic activity of the thiazolidinedione derivative CGP 52608 on central nervous system cancer cells. ( 15194216 )
2004
24
Nervous system cancer mortality in an industrialized area of Brazil 1980-1993. ( 10920400 )
2000
25
Exploitation of immune mechanisms in the treatment of central nervous system cancer. ( 10914414 )
2000
26
Risk of nervous system cancer among workers exposed to lead. ( 8673517 )
1996
27
Human malignant astrocytoma xenografts migrate in rat brain: a model for central nervous system cancer research. ( 2651679 )
1989
28
Brain and central nervous system cancer mortality in U. S. rubber workers. ( 6953785 )
1982

Variations for Nervous System Cancer

Expression for Nervous System Cancer

Search GEO for disease gene expression data for Nervous System Cancer.

Pathways for Nervous System Cancer

Pathways related to Nervous System Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 CASP3 CCND1 CDK2 CDK4 CDKN2A CDKN2B
2
Show member pathways
13.44 CCND1 CDK2 CDK4 CDKN2A CDKN2B RB1
3
Show member pathways
13.14 CDK2 CDK4 CDKN2A CDKN2B RB1 TP53
4
Show member pathways
13.04 CASP3 CCND1 CDK2 CDK4 RB1 RBL1
5
Show member pathways
13.01 CASP3 CCND1 CDK2 CDK4 CDKN2A RB1
6
Show member pathways
12.93 CASP3 CCND1 CDK2 CDK4 CDKN2A RB1
7 12.85 CASP3 CCND1 CDK2 CDK4 CDKN2A CDKN2B
8
Show member pathways
12.8 CCND1 CDK2 CDK4 CDKN2A CDKN2B RB1
9
Show member pathways
12.75 CCND1 CDK2 CDK4 CDKN2A CDKN2B NF1
10
Show member pathways
12.73 CASP3 CCND1 CDK2 CDK4 MGMT RB1
11
Show member pathways
12.58 CCND1 CDK2 CDK4 CDKN2A CDKN2B RB1
12 12.57 CCND1 CDK2 CDK4 CDKN2A MGMT RB1
13 12.51 CCND1 CDK2 CDK4 RB1 RBL1 TP53
14 12.43 CCND1 CDK4 CDKN2A CDKN2B RB1 TP53
15
Show member pathways
12.42 CCND1 CDK2 CDK4 RB1
16
Show member pathways
12.41 CASP3 CCND1 CDK2 CDK4 CDKN2A RB1
17 12.37 CCND1 CDK2 CDK4 CDKN2A CDKN2B RB1
18
Show member pathways
12.33 CASP3 CCND1 CDK2 CDK4 RB1 TP53
19
Show member pathways
12.32 CCND1 CDK2 CDK4 CDKN2A CDKN2B RB1
20
Show member pathways
12.31 CCND1 CDK2 CDK4 CDKN2A CDKN2B RB1
21 12.3 CASP3 CCND1 SHH TP53
22
Show member pathways
12.28 CASP3 CCND1 CDK2 CDK4 RB1 TP53
23 12.2 CASP3 CCND1 CDK2 CDK4 TP53
24 12.16 CASP3 CCND1 CDK2 CDK4 NF1 RB1
25 12.1 CCND1 CDKN2B RBL1 TP53
26
Show member pathways
12.09 CCND1 CDK2 CDK4 NF1
27 12.07 CDK2 CDKN2A RB1 TP53
28 12.07 CASP3 CCND1 CDK2 CDK4 RB1 TP53
29
Show member pathways
12.05 CCND1 CDK2 CDK4 RB1 RBL1 TP53
30 11.96 CCND1 CDK2 CDK4 CDKN2A CDKN2B RB1
31 11.93 CCND1 CDK2 CDK4 RB1 TP53
32 11.91 CASP3 CCND1 CDK2 CDK4 CDKN2A CDKN2B
33 11.89 CASP3 CCND1 CDK4
34 11.85 CDK2 CDK4 CDKN2B RBL1
35 11.83 CCND1 CDK4 CDKN2A RB1 TP53
36 11.77 CASP3 CCND1 CDK2 CDK4 CDKN2B RB1
37 11.75 CDK2 RB1 RBL1
38 11.75 CASP3 CDKN2A TP53
39
Show member pathways
11.75 CDK2 CDKN2A TP53
40 11.72 CDK2 CDKN2A RB1 TP53
41 11.71 CDK2 CDK4 RB1
42 11.66 CCND1 CDKN2B RBL1
43 11.65 CCND1 CDKN2A RB1 TP53
44 11.61 CCND1 CDK4 NF1
45 11.6 CASP3 CCND1 TP53
46 11.57 CASP3 CCND1 TP53
47 11.57 CCND1 CDK2 CDK4 TP53
48 11.54 CDK2 NF1 RB1
49 11.48 CCND1 CDK2 CDK4 RB1
50 11.46 CASP3 CDK2 CDK4 CDKN2B RB1 TP53

GO Terms for Nervous System Cancer

Cellular components related to Nervous System Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription factor complex GO:0005667 9.46 CDK2 CDK4 RB1 RBL1
2 cyclin-dependent protein kinase holoenzyme complex GO:0000307 9.13 CCND1 CDK2 CDK4
3 chromatin GO:0000785 8.92 CDK4 MYCN RB1 RBL1

Biological processes related to Nervous System Cancer according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.97 CASP3 CDK4 CDKN2A NF1 TP53
2 response to drug GO:0042493 9.92 BCHE CASP3 CCND1 CDK4 MGMT
3 regulation of cell proliferation GO:0042127 9.88 CDK4 NF1 NF2 SHH
4 negative regulation of gene expression GO:0010629 9.88 CDKN2B-AS1 MYCN RB1 RBL1 SHH
5 negative regulation of cell proliferation GO:0008285 9.87 BCHE CDKN2A CDKN2B NF1 NF2 RB1
6 cell cycle GO:0007049 9.86 CCND1 CDK2 CDK4 CDKN2A CDKN2B RB1
7 cell cycle arrest GO:0007050 9.84 CDKN2A CDKN2B RB1 TP53
8 response to organic substance GO:0010033 9.82 CASP3 CCND1 CDK4
9 response to organic cyclic compound GO:0014070 9.81 CASP3 CCND1 IDH1 MGMT
10 response to glucocorticoid GO:0051384 9.79 BCHE CASP3 CCND1
11 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.76 CDKN2B RB1 RBL1
12 negative regulation of protein kinase activity GO:0006469 9.73 NF1 NF2 RB1 CDKN2A
13 ectoderm development GO:0007398 9.65 NF2 SHH
14 replicative senescence GO:0090399 9.64 CDKN2A TP53
15 negative regulation of cell-matrix adhesion GO:0001953 9.63 CDKN2A NF1 NF2
16 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.62 MYCN TP53
17 response to folic acid GO:0051593 9.61 BCHE MGMT
18 regulation of protein localization to nucleus GO:1900180 9.59 NF2 SHH
19 striated muscle cell differentiation GO:0051146 9.58 SHH CASP3 RB1
20 regulation of lipid kinase activity GO:0043550 9.55 RB1 RBL1
21 G1/S transition of mitotic cell cycle GO:0000082 9.55 CCND1 CDK2 CDK4 CDKN2A RB1
22 mitotic G1 DNA damage checkpoint GO:0031571 9.54 CCND1 CDK2 TP53
23 glial cell apoptotic process GO:0034349 9.49 CASP3 RB1
24 Ras protein signal transduction GO:0007265 9.35 CDK2 CDKN2A NF1 RB1 TP53
25 regulation of cell cycle GO:0051726 9.1 RBL1 CDK4 CDK2 CCND1 NF2 RB1
26 positive regulation of transcription by RNA polymerase II GO:0045944 10.14 CDKN2A CDKN2B MYCN RB1 RBL1 SHH
27 negative regulation of transcription by RNA polymerase II GO:0000122 10.1 CCND1 CDK2 RB1 RBL1 SHH TP53
28 cellular response to DNA damage stimulus GO:0006974 10.03 CASP3 CCND1 CDK2 MGMT TP53
29 positive regulation of transcription, DNA-templated GO:0045893 10.03 CDK2 CDKN2A MYCN RB1 SHH TP53
30 positive regulation of gene expression GO:0010628 10 CDKN2A CDKN2B-AS1 MYCN SHH TP53

Molecular functions related to Nervous System Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 magnesium ion binding GO:0000287 9.67 CDK2 ENO2 IDH1 SUCLG2
2 transcription factor binding GO:0008134 9.65 CCND1 CDKN2A RB1 RBL1 TP53
3 RNA polymerase II regulatory region DNA binding GO:0001012 9.4 RB1 RBL1
4 disordered domain specific binding GO:0097718 9.33 CDKN2A RB1 TP53
5 cyclin-dependent protein serine/threonine kinase activity GO:0004693 8.96 CDK2 CDK4
6 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.8 CASP3 CDKN2A CDKN2B
7 protein binding GO:0005515 10.25 CASP3 CCND1 CDK2 CDK4 CDKN2A CDKN2B

Sources for Nervous System Cancer